Accelerated review https://www.bioworld.com/rss en-us By the numbers: US leads charge of cell and gene therapies http://www.bioworld.com/articles/713702 Tue, 22 Oct 2024 09:00:00 -0400 https://www.bioworld.com/articles/713702-by-the-numbers-us-leads-charge-of-cell-and-gene-therapies 3D rendering of CAR T therapy in cell By the numbers: US leads charge of cell and gene therapies http://www.bioworld.com/articles/713634 Fri, 18 Oct 2024 09:00:00 -0400 https://www.bioworld.com/articles/713634-by-the-numbers-us-leads-charge-of-cell-and-gene-therapies 3D rendering of CAR T therapy in cell Intercept faces a skeptical FDA in rare liver disease adcom http://www.bioworld.com/articles/712531 Fri, 13 Sep 2024 12:00:00 -0400 https://www.bioworld.com/articles/712531-intercept-faces-a-skeptical-fda-in-rare-liver-disease-adcom FDA approves Argenx's Vyvgart for rare autoimmune disease CIDP http://www.bioworld.com/articles/709890 Mon, 24 Jun 2024 12:00:00 -0400 https://www.bioworld.com/articles/709890-fda-approves-argenxs-vyvgart-for-rare-autoimmune-disease-cidp Vyvgart Hytrulo Credit: Argenx  Day One’s Ojemda approved in US for rare pediatric cancer http://www.bioworld.com/articles/707897 Tue, 23 Apr 2024 12:00:00 -0400 https://www.bioworld.com/articles/707897-day-ones-ojemda-approved-in-us-for-rare-pediatric-cancer A first: Biologics dominate 2023 class of accelerated approvals http://www.bioworld.com/articles/706690 Mon, 18 Mar 2024 12:00:00 -0400 https://www.bioworld.com/articles/706690-a-first-biologics-dominate-2023-class-of-accelerated-approvals Vial and syringe with molecule structure